Understanding Health Insurance Support for Targeted Therapy
Navigating the financial aspects of cancer treatment can be challenging. Fortunately, current national health insurance regulations provide partial financial assistance for specific targeted therapy drugs listed in the approved medical formulary. This significantly alleviates the financial burden for cancer patients undergoing precision medicine regimens.
Covered Targeted Drugs and Reimbursement Rates
Health insurance schemes currently subsidize first- and second-generation targeted drugs, particularly for non-small cell lung cancer harboring EGFR mutations:
- First- and Second-Generation Tyrosine Kinase Inhibitors (TKIs): Medications such as Gefitinib, Erlotinib, and Afatinib are covered at a 50% co-payment rate.
Mandatory Criteria to Qualify for Insurance Coverage
To access these insurance benefits and reduce treatment costs, patients must satisfy several key medical and administrative requirements:
- Valid Insurance Status: Holding an active and valid health insurance card.
- Proper Referral Channel: Undergoing treatment at the registered hospital tier or having a legitimate, approved medical referral document.
- Confirmed Genetic Mutation: Presenting verifiable diagnostic laboratory results demonstrating actionable gene mutations that match the drug’s approved profile.
- Authorized Medical Prescription: Using the medication strictly under the supervision and prescription of a licensed oncologist.
Out-of-Network and Non-Formulary Considerations
Patients who receive treatment out-of-network without a valid transfer, or who require novel therapies that are not yet included in the standard health insurance formulary, will typically need to cover the entire cost of the medication out of pocket.
